Competitor Landscape: Non-alcoholic Steatohepatitis (NASH)

Competitor Landscape: Non-alcoholic Steatohepatitis (NASH)


Competitor Landscape: Non-alcoholic Steatohepatitis (NASH), briefings contain evaluations of ongoing development activities within the Non-Alcoholic Steatohepatitis (NASH) disease market, together with analysis of current & potential future product positioning.

Key Highlights from the report -

  • Phase II NCT02787304 trial has been discontinued, and the future of SHP626 (volixibat) in NASH is currently uncertain
  • Topline results for Phase IIb NATIVE trial of lanifibranor in NASH are currently expected in H1 2020 (delayed from the original schedule of mid-2018 due to slow patient enrollment)
  • Medicinova will likely initiate a Phase IIb trial for MN-001 with biopsy-based endpoints, which could begin at any time
The report comprises three sections -

Executive Summary
  • Contains analysis of key market events that have occurred during the previous month and which have impacted the NASH landscape.
Landscape Updates
  • ‘Order of Entry’ analysis, detailing timeline forecasts for each drug in Phase II development or higher.
  • Timeline forecasts for each approved product’s lifecycle management initiatives.
  • ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline therapies.
Pipeline Landscape
  • An overview of pipeline candidates, containing snapshots of current development status.
  • Expected drug-specific events & milestones until YE 2020.
  • Current early stage RA pipeline & candidate ‘Watch List’.
  • Timeline assumptions, including standard assumptions & drug-specific assumptions.
  • The briefing is based on Sociable Pharma’s analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (
  • Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher - these are outlined in the report Appendix
  • Forecasts are presented in pipeline forecast figures & detailed tables
  • ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies is also provided.
Reasons to buy
  • Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher
  • Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market
  • Reviews ongoing lifecycle management strategies for existing players in the market
  • A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.

Introduction to Sociable Pharma’s ‘Competitor Landscape’
Executive Summary
Key Events & Landscape Updates
Landscape Updates
Order of Entry
Key Competitor Market Entry Strategies
Lifecycle Development
Key Competitor ‘Direction of Travel’
Pipeline Landscape
Pipeline Summary

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook